|
1
|
Leporrier J, Maurel J, Chiche L, Bara S,
Segol P and Launoy G: A population-based study of the incidence,
management and prognosis of hepatic metastases from colorectal
cáncer. Br J Surg. 93:464–474. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Krell RW and D'Angelica M: Treatment
sequencing for simultaneous colorectal liver metastases. J Surg
Oncol. 119:583–593. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cirocchi R, Trastulli S, Abraha I,
Vettoretto N, Boselli C, Montedori A, Parisi A, Noya G and Platell
C: Nonresection versus resection for asymptomatic primary tumour in
patients with unresectable stage IV colorectal cáncer. Cochrane
Database Syst Rev. 8(CD008997)2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Aslam MI, Kelkar A, Sharpe D and Jameson
JS: Ten years' experience of managing the primary tumours in
patients with stage IV colorectal cancers. Int J Surg. 8:305–313.
2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sanoff HK, Sargent DJ, Campbell ME, Morton
RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC
and Goldberg RM: Five-year data and prognostic factor analysis of
oxaliplatin and irinotecan combinations for advanced colorectal
cáncer: N9741. J Clin Oncol. 26:5721–5727. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initialtreatment for
metastatic colorectal cáncer. N Engl J Med. 360:1408–1417.
2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ahmed S, Shahid RK, Leis A, Haider K,
Kanthan S, Reeder B and Pahwa P: Shoudnoncurative resection of the
primary tumor be performed in patients with stage IV colorectal
cáncer? A systematic review and meta-analysis. Curr Oncol.
20:e420–441. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Stillwell AP, Buettner PG and Ho YH:
Meta-analysis of survival of patients with stage IV colorectal
cáncer managed with surgical resección versus chemotherapy alone.
World J Surg. 34:797–807. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cáncer. Ann Oncol.
27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Messersmith WA: NCCN guidelines updates:
Management of metastatic colorectal cancer. J NatlCompr Cancer
Netw. 17:599–601. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Alawadi Z, Phatak UR, Hu CY, Bailey CE,
You YN, Kao LS, Massarweh NN, Feig BW, Rodriguez-Bigas MA, Skibber
JM and Chang GJ: Comparative effectiveness of primary tumor
resection in patients with stage IV colon cáncer. Cancer.
123:1124–1133. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lee K, Ou Y, Hu WH, Liu CC and Chen HH:
Meta-analysis of outcomes of patients with stage IV colorectal
cáncer managed with chemotherapy/radiochemotherapy with and without
primary tumor resection. Onco Targets Ther. 9:7059–7069.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hu CY, Bailey CE, You YN, Skibber JM,
Rodriguez-Bigas MA, Feig BW and Chang GJ: Time trend analysis of
primary tumor resection for stage IV colorectal cáncer: Less
surgery, improved survival. JAMA Surg. 150:245–251. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tarantino I, Warschkow R and Güller U:
Palliative primary tumor resection in patients with metastatic
colorectal cancer: For whom and when? Ann Surg. 265:e59–e60.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mehta HB, Vargas GM, Adhikari D, Dimou F
and Riall TS: Comparative effectiveness of chemotherapy vs
resection of the primary tumour as the initial treatment in older
patients with stage IV colorectal cáncer. Colorectal Dis.
19:O210–O218. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tominaga T, Nonaka T, Shiraisi T, Hamada
K, Noda K, Takeshita H, Maruyama K, Fukuoka H, Wada H, Hashimoto S,
et al: Factors related to short-term outcomes and delayed systemic
treatment following primary tumor resection for asymptomatic stage
IV colorectal cáncer. Int J Colorectal Dis. 35:837–846.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rehman A, Jones RP and Poston G:
Prognostic and predictive markers in liver limited stage IV
colorectal cáncer. Eur J Surg Oncol. 45:2251–2256. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yarom N, Gresham G, Boame N and Jonker D:
KRAS status as a predictor of chemotherapy activity in patients
with metastatic colorectal cancer. Clin Colorectal Cancer.
18:e309–e315. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yeom SS, Lee SY, Kwak HD, Kim CH, Kim YJ
and Kim HR: The outcome of primary tumor resection in the
unresectable stage IV colorectal cáncer patients who received the
bevacizumab-containing chemotherapy. Medicine (Baltimore).
99(e19258)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Andreyev HJ, Norman AR, Cunningham D,
Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N,
et al: Kirsten ras mutations in patients with colorectal cáncer:
The RASCAL II study. Br J Cancer. 85:692–696. 2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Phipps AI, Buchanan DD, Makar KW, Win AK,
Baron JA, Lindor NM, Potter JD and Newcomb PA: KRAS-mutation status
in relation to colorectal cancer survival: The joint impact of
correlated tumour markers. Br J Cancer. 108:1757–1764.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tapia Rico G, Price T, Tebbutt N,
Hardinghamm J, Lee C, Buizen L, Wilson K, Gebski V and Townsend A:
Right or left primary site of colorectal cancer: Outcomes from the
molecular analysis of the AGITG MAX trial. Clin Colorectal Cancer.
18:141–148. 2018.
|
|
24
|
Ulanja MB, Rishi M, Beutler BD, Sharma M,
Patterson DR, Gullapalli N and Ambika S: Colon cancer sidedness,
presentation and survival at different stages. J Oncol.
2019(4315032)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Imamura Y, Morikawa T, Liao X, Lochhead P,
Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis
KM, et al: Specific mutations in KRAS codons 12 and 13, and patient
prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer
Res. 18:4753–4763. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rasmy A, Fayed A, Omar A and Fahmy N:
Effect of KRAS mutational status on disease behavior and
treatment outcome in patients with metastatic colorectal cáncer:
Intratumor heterogeneity and mutational status. J
GastrointestOncol. 10:886–895. 2019.PubMed/NCBI View Article : Google Scholar
|
